Aliya Khan is a Clinical Professor of Medicine, Division of Endocrinology and Geriatrics, Director of the Calcium Disorders Clinic, and Director of the Fellowship in Metabolic Bone Disease at McMaster University.  She graduated from the University of Ottawa Medical School with honors. She trained in Internal Medicine, Geriatric Medicine and Endocrinology and completed a fellowship in Metabolic Bone Disease at the University of Toronto.  She has published over 400 scientific papers and numerous chapters and books on osteoporosis and parathyroid disease. She led the development of global guidelines for parathyroid disease, osteonecrosis of the jaw, new diagnostic criteria for hypophosphatasia, treatment guidelines for  X-linked hypophosphatemia in addition to osteoporosis guidelines.

She is the co-chair  of the International Working Group developing best practice recommendations on bone mineral density reporting supported by 10 international imaging and skeletal health societies. She is a leading clinician researcher and is the principle investigator evaluating novel therapies for parathyroid disease including PTH , PTH analogues as well PTH1receptor agonists for  hypoparathyroidism.

She has received numerous international awards for outstanding contributions to Medicine including the Queen’s Diamond Jubilee Medal, International Osteoporosis Foundation award ,  Osteoporosis Canada Lindy Fraser award, Woman Physician of the Year Award  by the American College of Physicians, Canadian Society of Endocrinology and Metabolism Dr. Jacques Genest Lecture Award.  ORTOMED Medal from the Italian Society of Orthopedics and Medicine,  King Charles Coronation medal and 2025 American Association of Clinical Endocrinologists Outstanding International Clinician award. She was awarded the FIRMO Parathyroid Medal at the Endocrine Society pre-meeting in 2025 in recognition of her outstanding contributions to advancing research in parathyroid disease. She is recognized as being in the top 0.1% of the world experts in hyperparathyroidism by Expertscape.

The BREC is a Centre of Excellence in the Diagnosis and Management of Metabolic Bone Disease, Calcium and Parathyroid Disorders. The goals and objectives of the BREC are:

1. To deliver state of the art clinical care to people with metabolic bone disease or calcium and parathyroid disorders.

2. Advance clinical research in understanding the mechanisms for disease development and development of new drug therapy

3. Disseminate knowledge providing physicians both generalists and specialists with the tools to diagnose and treat bone diseases and calcium disorders.

4. Provide an onsite multi-media learning center for patients and physician

The Center will provide clinical care with on-site diagnosis and management of complex metabolic bone diseases, calcium, and parathyroid diseases. Clinical research will focus on developing new therapies for osteoporosis, renal osteodystrophy, and parathyroid diseases. Bone biopsies will continue to be completed at Halton Healthcare Services. Bone Density studies will be completed on-site.